Clinical Trials Using Radium Ra 223 Dichloride

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Radium Ra 223 Dichloride. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-17 of 17
  • Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

    This study is designed to assess the safety and tolerability of atezolizumab when given in combination with radium-223 dichloride in participants with metastatic CRPC who have progressed after treatment with an androgen pathway inhibitor. This adaptive design study includes a cohort phase and a potential randomization phase. An initial concurrent dosing evaluation will evaluate the safety and tolerability of a treatment regimen that employs a concurrent start time for atezolizumab and radium-223 dichloride (Cohort 1). If concurrent dosing is found to be safe and tolerable in Cohort 1, additional participants will be enrolled and eligible participants will be randomized in a 1:1:1 ratio to Arms A, B, and C. If concurrent dosing is not tolerated in Cohort 1, new participants will be enrolled in a staggered dosing evaluation: Cohort 2 (28-day radium-223 dichloride run-in, atezolizumab will begin on Day 1 of Cycle 2) and Cohort 3 (56-day radium-223 dichloride run-in, atezolizumab will begin on Day 1 of Cycle 3). If the Cohort 2 schedule is tolerable, then additional participants will be enrolled using this treatment schedule; If the Cohort 2 schedule is not tolerable, subsequent participants will be enrolled in Cohort 3. If the Cohort 3 schedule is tolerable, then additional participants will be enrolled using this treatment schedule. If Cohort 3 schedule is not tolerable, no additional participant will be enrolled in the study.
    Location: 11 locations

  • Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

    The objective of this study is to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy.
    Location: 6 locations

  • Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

    The objective of this study is to assess efficacy and safety of radium 223 dichloride in subjects with human epidermal growth factor receptor 2 (HER2) negative hormone receptor positive breast cancer with bone metastases treated with exemestane and everolimus.
    Location: 5 locations

  • Pembrolizumab and Radium Ra 223 Dichloride in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This randomized phase II trial studies how well pembrolizumab and radium Ra 223 dichloride work in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Pembrolizumab works to block the PD-1 pathway, which plays an important role in lessening the activity of one’s immune system to fight cancer. Pembrolizumab is therefore referred to as a PD-1 inhibitor, and acts by stimulating the patient’s T cells, which are important immune cells, to attack tumors and treat cancer. Radium-223 targets cancer that exists in the bone directly. Radium-223 binds to minerals in the bone to deliver radiation directly to the tumor that has spread to the bones while limiting damage to the surrounding body tissues. Giving pembrolizumab and radium Ra 223 dichloride together may work better in treating patients with castration-resistant prostate cancer.
    Location: 3 locations

  • Rapid Cycle Combination Therapy in Treating Patients with Metastatic Castrate-Resistant Prostate Cancer

    This phase II trial studies how well rapid cycle combination therapy works in treating patients with prostate cancer that has not responded to surgery or hormone therapy and has spread to other places in the body. Androgen can cause the growth of tumor cells. Antihormone therapy, such as abiraterone acetate and enzalutamide, may lessen the amount of androgen made by the body. Drugs used in the chemotherapy, such as radium Ra 223 dichloride, cabazitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Switching between different combinations of androgen deprivation therapy and chemotherapy after a short time may prevent drug resistance and help achieve better long-term control of prostate cancer.
    Location: 3 locations

  • Radium Ra 223 Dichloride and Niraparib in Treating Patients with Hormone- Resistant Prostate Cancer Metastatic to the Bone

    This phase Ib trial studies the side effects and best dose of niraparib when given together with radium Ra223 dichloride in treating patients with prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels and has spread from the primary site to the bone. Radium Ra 223 dichloride, acts like calcium to target cancer in the bones and may deliver radiation directly to the bone tumors, limiting damage to the surrounding normal tissue. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving radium Ra 223 dichloride and niraparib may work better in treating patients with hormone-resistant prostate cancer metastatic to the bone.
    Location: 2 locations

  • Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

    This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with relapsed multiple myeloma. The primary endpoint is to determine the optimal dose of radium-223 dichloride in combination with bortezomib / dexamethasone for the Phase 2 portion of the study. The phase 2 part will be an international, phase 2, double-blind, randomized, placebo-controlled assessment of radium-223 dichloride versus placebo administered with bortezomib and dexamethasone, in subjects with relapsed multiple myeloma. Up to approximately 30 total subjects in all dose cohorts combined will be treated in the phase 1b part of the study and approximately 196 subjects will be enrolled in the phase 2 part of the study.
    Location: 2 locations

  • Sipuleucel-T with or without Radium Ra 223 Dichloride in Treating Patients with Asymptomatic or Minimally Symptomatic Bone-Metastatic Hormone-Resistant Prostate Cancer

    This randomized phase II trial studies how well sipuleucel-T with or without radium Ra 223 dichloride works in treating patients with asymptomatic (no signs or symptoms of disease) or minimally symptomatic hormone-resistant prostate cancer that has spread to the bone (metastasis). Sipuleucel-T is made of immune system cells collected from patients with prostate cancer that are treated in the laboratory with a protein that is made by combining a protein found on prostate cancer cells with a growth factor. When the cells are injected back into the patient, they may stimulate T cells to kill prostate cancer cells. Radium 223 dichloride contains a radioactive substance called radium 223. Radium 223 collects in bone and gives off radiation that may kill cancer cells. It is not yet know whether sipuleucel-T with or without radium Ra 223 dichloride works is an effective treatment for patients with bone-metastasis hormone resistant prostate cancer.
    Location: 2 locations

  • Radium Ra 223 Dichloride in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This phase II trial studies how well radium Ra 223 dichloride works in treating patients with prostate cancer that has spread to the bone (metastatic) and is resistant to hormone therapy. Radium Ra 223 dichloride is a radioactive drug that may kill tumor cells by damaging the tumor cells deoxyribonucleic acid (DNA) with limited toxicity to nearby healthy bone tissue. Studying samples of blood in the laboratory from patients receiving radium Ra 223 dichloride may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors understand how well patients respond to treatment.
    Location: 2 locations

  • Radium Ra 223 Dichloride and Atezolizumab in Treating Patients with Bladder Cancer That Has Spread to the Bone

    This pilot clinical trial studies how well radium Ra 223 dichloride and atezolizumab work in treating patients with bladder cancer that has spread to the bone. Radioactive drugs, such as radium Ra 223 dichloride, may carry radiation directly to tumor cells and not harm normal cells. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving radium Ra 223 dichloride and atezolizumab may work better in treating patients with bladder cancer that has spread to the bone.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Androgen Deprivation Therapy + / - Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

    Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Radium Ra 223 Dichloride, Hormone Therapy, and Denosumab in Treating Patients with Hormone-Positive, Bone-Dominant Metastatic Breast Cancer

    This phase II trial studies how well radium Ra 223 dichloride, hormone therapy, and denosumab work in treating patients with hormone-positive breast cancer that has spread from the primary site to the bones and / or bone marrow (bone-dominant metastatic). Radioactive drugs, such as radium Ra 223 dichloride, may carry radiation directly to bone-dominant metastatic breast cancer and not harm normal cells. Hormones can cause the growth of breast cancer cells. Drugs, such as anastrozole, exemestane, fulvestrant, letrozole, and tamoxifen citrate, may lessen the amount of hormones made by the body. Monoclonal antibodies, such as denosumab, may block tumor growth in different ways by targeting certain cells. Giving radium Ra 223 dichloride, hormone therapy, and denosumab may help to control breast cancer that has spread to the bones and / or bone marrow.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Radium Ra 223 Dichloride and Enzalutamide in Treating Patients with Metastatic Prostate Cancer That Is Resistant to Antihormone Therapy

    This randomized phase II trial studies how well radium Ra 223 dichloride and enzalutamide work in treating patients with prostate cancer that has spread to other places in the body (metastatic) and does not respond to treatment with antihormone therapy. Radium Ra 223 dichloride contains a radioactive substance that collects in the bone and gives off radiation that may kill cancer cells. Enzalutamide may stop the growth of tumor cells by binding and blocking proteins called androgen receptors that are needed for cell growth. Giving radium Ra 223 dichloride with enzalutamide may be an effective treatment for prostate cancer.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Radium Ra 223 Dichloride in Reducing Pain in Patients with Symptomatic Metastatic Castration-Resistant Prostate Cancer

    This phase II trial studies how well radium Ra 223 dichloride works in reducing pain in patients with prostate cancer that exhibits symptoms, has spread to bones in the body, and does not respond to treatment with hormones. Radium Ra 223 Dichloride is a mineral similar to calcium that delivers radiation therapy to bone metastases. Radium Ra 223 dichloride may also help relieve pain caused by prostate cancer.
    Location: 3 locations

  • Carbon-11 Acetate PET / CT Imaging in Evaluating Response to Radium Ra 223 Dichloride Therapy in Patients with Hormone-Resistant Metastatic Prostate Cancer

    This pilot clinical trial studies carbon-11 acetate positron emission tomography / computed tomography (PET / CT) in evaluating response to radium Ra 223 dichloride therapy in patients with prostate cancer that has not responded to previous treatment with hormones and that has spread to the bones. Carbon-11 acetate is a specialized radioactive drug that is used to allow imaging of tissue using a PET / CT scanner which is specialized to detect a small radioactive signal. Carbon-11 acetate is used to evaluate cell growth and how fast cells replicate. The amount of carbon-11 acetate that is taken up by cancer cells before and after radium Ra 223 therapy may help to understand whether patients with hormone-resistant metastatic prostate cancer are responding to treatment.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )

    Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.
    Location: Wayne State University / Karmanos Cancer Institute, Detroit, Michigan

  • Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

    Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.
    Location: Wake Forest University Health Sciences, Winston-Salem, North Carolina